Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 12/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670201 | 0.86 | PDPK1 (0.59) | PDPK1ALDH1A1SMN1; SMN2LMNAPDE10A | |
| Bromide SCHEMBL5669202 | 0.85 | PDPK1 (0.57) | PDPK1ALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL8583785 | 0.83 | PARP1 (0.49) | PARP1PARP2PARP3LIMK1 | |
| SCHEMBL30874474 | 0.81 | PARP1 (0.47) | PARP1PARP2PARP3 | |
| SCHEMBL9722753 | 0.81 | CYP3A4 (0.56) | PDPK1ALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL23857795 | 0.79 | UBE2T (0.47) | ALDH1A1PARP1PARP2PARP3 | |
| SCHEMBL2793048 | 0.77 | ALDH1A1 (0.49) | PDPK1ALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL9722823 | 0.77 | ALDH1A1 (0.53) | PDPK1ALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL316533 | 0.75 | PARP1 (0.52) | ALDH1A1SMN1; SMN2LMNAPARP1 | |
| SCHEMBL10726562 | 0.75 | PARP1 (0.45) | PARP1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553848-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1725529-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | Amgen Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005070885-A1 | BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165046-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDPK1 2737/4885ALDH1A1 3014/4885SMN1; SMN2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.